StemCell Technologies' Contract Services Presents Educational Webinar on Use of Hematopoietic Stem Cell Assays in Detection and Characterization of Chemokine and Cytokine Activity

Share Article

High content assays for efficient and cost effective evaluation of the potential of compounds to alter or expand hematopoietic stem and progenitor cell populations

Stem Cell Technologies (STI), a world leader in the development of technologies for stem cell biology, is pleased to announce that STI Contract Services ( will be providing a free, educational webinar on the detection and characterization of chemokine and cytokine activity using hematopoietic stem and progenitor cell assays.

"Cytokines and Chemokines In Hematopoiesis", will be presented by Dr. Jackie Damen on January 17, 2007 at 11:00 AM PST (2:00 PM EST). Register online by visiting

The following topics will be discussed:

  •     advantages of stem and progenitor cell assays for evaluating the potential of compounds to alter or expand hematopoietic cell populations
  •     regulation of hematopoietic stem and progenitor cell proliferation and differentiation
  •     applications of related in vitro and in vivo assays

About Stemcell Technologies Inc. Contract Services

StemCell Technologies is a world leader in the development of products for stem cell biology and has worked to standardize the field through the Global Proficiency Testing Program. Combining StemCell Technologies' industry standard reagents and a scientific team of experts in hematopoiesis and stem cell biology, StemCell Technologies is proud to assist organizations in drug development, agrochemical production, environmental toxicant testing and the research community by offering Contract Services.

About Dr. Jackie Damen

Following completion of her PhD (1990) at the University of Manitoba, Jackie performed her post-doctoral training at the Terry Fox Laboratory in Vancouver BC characterizing signal transduction pathways downstream of the mouse Eyrthropoietin Receptor. She also identified a novel signalling intermediate involved in the regulation of many hematopoietic pathways.

Dr Damen then joined Chemokine Therapeutics as Director of Biology and initiated studies using mouse models to investigate hematopoietic modulation in response to synthetic compounds. She joined StemCell Technologies in January, 2002 to optimise novel protein purification protocols and is currently R&D Senior Scientist and Laboratory Manager of Contract Services at StemCell Technologies, Inc.

Dr Damen has authored numerous scientific papers and is a frequent speaker and presenter at national and international meetings.


Rob Chaney

Director of Business Development, STI Contract Services


# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Rob Chaney
Visit website